Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Alteplase Placebo Clear all
Completed Phase 2 Interventional

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

NCT04918719
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Acetylcysteine, Dextrose in Water
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 5, 2026, 4:04 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

NCT03594175
View directory record Official record
Conditions
Catheter Occlusion, Thrombosis
Interventions
CUSA-081, Placebo, Alteplase
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
35
States / cities
Little Rock, Arkansas • Redlands, California • Stockton, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)

NCT01595516
View directory record Official record
Conditions
Prehypertension, Hypertension
Interventions
Nebivolol, Metoprolol, Placebo, Bradykinin, Saline, Vitamin C
Drug · Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
45 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 5, 2026, 4:04 AM EDT
Terminated Phase 1Phase 2 Interventional

Transcranial Ultrasound in Clinical SONothrombolysis

NCT00504842
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
MRX-801, Placebo
Drug
Lead sponsor
ImaRx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2008 · Synced Sep 5, 2026, 4:04 AM EDT
Not listed Not applicable Interventional

Aureva Transcranial Ultrasound Device With tPA in Patients With Acute Ischemic Stroke

NCT03519737
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
tPA in combination with the Sonolysis Headframe (TUS), tPA in combination with the Sonolysis Headframe (Sham TUS)
Device
Lead sponsor
Cerevast Medical, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Memphis, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Results available

Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis

NCT04806373
View directory record Official record
Conditions
Pleural Effusion
Interventions
Cathflo Activase, Talc Slurry Pleurodesis
Drug
Lead sponsor
Memorial Healthcare System
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)

NCT00044057
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
YM872 (zonampanel), t-PA (alteplase)
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
94
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2006 · Synced Sep 5, 2026, 4:04 AM EDT
Terminated Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke

NCT02072226
View directory record Official record
Conditions
Stroke
Interventions
Alteplase, Alteplase Placebo, Aspirin, Aspirin Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III

NCT00784134
View directory record Official record
Conditions
Intraventricular Hemorrhage
Interventions
Alteplase, Normal saline
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

NCT01413542
View directory record Official record
Conditions
Hypertension, Diabetes Type 2
Interventions
Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin, enalaprilat (ACE inhibitor), Glucagon-like peptide 1, brain natriuretic peptide
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Not applicable Interventional Results available

Efficacy and Safety of Activase (Ateplase) vs Placebo in Complicated Pleural Effusions (CPE)/Empyemas

NCT00468104
View directory record Official record
Conditions
Pleural Effusion Associated With Pulmonary Infection, Bacterial Pleural Effusion Other Than Tuberculosis
Interventions
Alteplase, Placebo
Drug
Lead sponsor
Midwest Pulmonary and Critical Care
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 5, 2026, 4:04 AM EDT
Terminated Phase 4 Interventional Results available

Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism

NCT04558125
View directory record Official record
Conditions
Pulmonary Embolism, COVID
Interventions
TNKase, Placebo, Enoxaparin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 5, 2026, 4:04 AM EDT
Terminated Phase 3 Interventional

Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke

NCT01098981
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Transcranial ultrasound as an adjunctive therapy to tPA, Standard of care tPA therapy for acute ischemic stroke
Device · Drug
Lead sponsor
Cerevast Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 5, 2026, 4:04 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage

NCT01878136
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Cerebral Vasospasm, Cerebral Aneurysm, Hydrocephalus
Interventions
Tissue Plasminogen Activator
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Sep 5, 2026, 4:04 AM EDT
Recruiting Early Phase 1 Interventional

Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion

NCT06184321
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Alteplase, Placebo Administration
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

Tenecteplase in Patients With COVID-19

NCT04505592
View directory record Official record
Conditions
COVID-19, Respiratory Failure, ARDS
Interventions
Tenecteplase, Placebo
Drug
Lead sponsor
Hooman Poor
Other
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 5, 2026, 4:04 AM EDT
Terminated Phase 2 Interventional

Evaluation of MST-188 in Acute Lower Limb Ischemia

NCT02093468
View directory record Official record
Conditions
Acute Limb Ischemia
Interventions
MST-188, Saline
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
4
States / cities
Little Rock, Arkansas • Tampa, Florida • Brooklyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion

NCT01222117
View directory record Official record
Conditions
Acute Peripheral Arterial Occlusion
Interventions
Plasmin, Plasminogen Activator, Placebo
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Sep 5, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

Tenecteplase in Stroke Patients Between 4.5 and 24 Hours

NCT03785678
View directory record Official record
Conditions
THROMBOLYSIS
Interventions
Tenecteplase, Placebo
Biological · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
94
States / cities
Birmingham, Alabama • Mesa, Arizona • Anaheim, California + 74 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 5, 2026, 4:04 AM EDT
Terminated Phase 4 Interventional Results available

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

NCT03988842
View directory record Official record
Conditions
Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism, Pulmonary Embolism With Pulmonary Infarction, Pulmonary Embolism Subacute Massive, Right Ventricular Dysfunction, Right Ventricular Failure
Interventions
Alteplase, Unfractionated heparin, Placebo, Apixaban
Drug
Lead sponsor
Victor Tapson, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 5, 2026, 4:04 AM EDT